Core Viewpoint - StealthGas reported a successful year in 2025, achieving high profitability despite geopolitical challenges, with an adjusted net income of $65.6 million, marking the second highest in its history [4]. Financial Performance - The company maintained high profits consistently for the last four years, indicating effective strategic execution [4]. - The fourth quarter results showed a decline, suggesting some challenges faced during this period [4].

Core Viewpoint - The webcast presentation for National Healthcare Properties, Inc. focuses on the Fourth Quarter and Full Year 2025 results, highlighting forward-looking statements and financial measures [1][2][3]. Group 1: Forward-Looking Statements - The company will present forward-looking statements that are subject to certain assumptions and risk factors, which may lead to actual results differing from these statements [2]. - These statements are made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 [1]. Group 2: Financial Measures - The company will discuss non-GAAP financial measures during the call, which should not be viewed in isolation or as a substitute for GAAP financial results [3]. - A reconciliation of these non-GAAP measures to the most directly comparable GAAP measure will be provided in the fourth quarter 2025 earnings supplemental on the company's website [3]. Group 3: Presentation Logistics - Questions can be submitted during the webcast, and the Investor Relations team will follow up after the presentation [4]. - A copy of the presentation and a replay of the webcast will be available on the company's website later today [4].

Financial Data and Key Metrics Changes - Revenue in Q4 2025 was $82.3 million, down 23% from $106.9 million in Q4 2024 [10] - Non-GAAP EPS for Q4 was $0.02, compared to $0.09 in Q4 2024 [13] - Full year revenue for 2025 was $338.7 million, a decline of 14.1% from $394.2 million in 2024 [14] - Non-GAAP net income for 2025 was $8.2 million, or $0.09 per diluted share, down from $36.4 million, or $0.41 per diluted share in 2024 [15] - Cash position at the end of 2025 was $38.4 million, compared to $35.3 million at the end of 2024, with a net cash position of $19.4 million, up from $10.1 million at the end of 2024 [15][16] Business Line Data and Key Metrics Changes - Strongest regions in Q4 2025 were North America and India, generating $32.3 million and $24.7 million in revenue, respectively [10] - Non-GAAP gross profit for Q4 was $28.2 million, a decrease of 23.2% compared to $36.7 million in Q4 2024, with a non-GAAP gross margin of 34.3% [11] Market Data and Key Metrics Changes - The company expects 2026 revenue to be between $355 million and $385 million, based on backlog advancement in North America and a baseline of $100 million in annualized revenue from India [7][18] - Early activity in 2026 supports confidence in continued progress on revenue cadence, margins, and cash generation [9] Company Strategy and Development Direction - The company plans to launch four new products in 2026, with some expected to generate initial revenue this year [5] - Focus remains on execution, differentiation, and conversion, prioritizing opportunities with clear customer demand [6] - The company aims to improve non-GAAP gross margin by approximately 1 percentage point at the midpoint of the revenue range through improved revenue mix and cost reduction initiatives [18] Management's Comments on Operating Environment and Future Outlook - Management sees steady traction across markets, with customer engagement and initial orders reflecting positive trends [19] - The outlook for 2026 remains intact, with early activity in the year reinforcing confidence in demand [5][9] - Management is closely monitoring foreign exchange fluctuations and has a hedging policy in place [27] Other Important Information - The company reported positive free cash flow in excess of $7 million for Q4 2025 [10] - Inventory at the end of 2025 was $61.6 million, up slightly from $59.7 million at the end of 2024 [16] Q&A Session Summary Question: What would be needed to hit the high end of your 2026 guidance? - Management indicated that a combination of stronger performance in North America and India, along with recovery in other regions, could help reach the high end of the guidance [21][22] Question: Can you talk about dollar to shekel issues and how you are handling that? - Management stated they are monitoring foreign exchange and have a hedging policy in place, noting that a 1% change could impact operating margin by 0.1% [25][27] Question: How do you see the balance of the first half versus the second half of 2026? - Management expects the second half of the year to be stronger than the first, despite typical seasonality affecting Q1 revenue [28] Question: Can you comment on the level of activity in the Asia-Pacific region for private networks? - Management noted multiple opportunities in private networks across all regions, with significant potential in APAC, particularly in mining and energy sectors [31] Question: Can you provide an update on your major Tier 1 customer in North America? - Management reported that the customer continues to invest in their network, with opportunities for new use cases around network resiliency [38] Question: How are you addressing supply chain and memory costs? - Management indicated that the issue is primarily price-related rather than supply-related, and they are working on building second and third sources for memory components [41]

Financial Data and Key Metrics Changes - IRadimed achieved record revenue for the 18th consecutive quarter, with Q4 2025 revenue reaching $22.7 million, a 17% increase from Q4 2024, and full-year revenue of $83.8 million, up 14% year-over-year [3][10] - GAAP diluted earnings per share for Q4 was $0.50, up 25%, and for the full year, it reached $1.75, up 17% [3][12] - Gross margins remained strong at approximately 77% for the year and 75% for Q4 [3][11] Business Line Data and Key Metrics Changes - MRI-compatible infusion pump systems contributed $9.1 million in Q4, up 20% year-over-year, while patient vital signs monitoring systems contributed $7.1 million, up 7.5% [10] - Disposable revenue grew 18% to $4.3 million, reflecting increased utilization of devices [10][11] Market Data and Key Metrics Changes - Domestic sales accounted for 81% of total revenue in Q4 and 84% for the full year, indicating strong U.S. performance [11] - There are approximately 6,400 5+-year-old 3860/3861 pump channels in the U.S. market that are up for replacement [6] Company Strategy and Development Direction - The company anticipates a significant increase in revenue from the replacement of older pump models, which is expected to be a key growth driver for the next several years [5][7] - The new 3870 MR IV pump is expected to penetrate greenfield opportunities more effectively and increase utilization among existing customers [4][5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a $100 million-plus revenue run rate during 2026, driven by the new 3870 pump and increased disposable sales [7][8] - The company plans to maintain quarterly revenue in the first half of 2026, with significant growth expected in the second half [8] Other Important Information - The company ended the year with cash and cash equivalents of $51.2 million, and cash flow from operations was $5.9 million for Q4 and $24.9 million for the full year [12] - The company is working on a next-generation MRI monitor expected to launch in 2028 [21] Q&A Session Summary Question: Initial market feedback from the pilot - Management reported very positive feedback from initial users of the 3870 pump, leading to confidence in scaling the launch [15][16] Question: Gross margin scaling - Management indicated that gross margins are expected to remain stable in the first half of the year but may improve in the second half due to higher volumes and ASP [18][19] Question: Updates on disposables and services growth - Management noted that disposable revenue growth is expected to align with capital sales, with potential for increased utilization with the new 3870 pump [26][27] Question: Inventory levels and backlog for the 3860 - Management stated that inventory levels are being closely monitored to ensure fulfillment of backlog while transitioning to the 3870 [28][29] Question: Regulatory process for 3870 in Europe and Japan - Management confirmed that CE mark approval is expected by the end of 2026, with Japan clearance anticipated by summer 2027 [32]

Financial Data and Key Metrics Changes - IRadimed achieved record revenue for the 18th consecutive quarter, with Q4 2025 revenue reaching $22.7 million, a 17% increase from Q4 2024, and full-year revenue of $83.8 million, up 14% year-over-year [3][10] - GAAP Diluted Earnings Per Share for Q4 was $0.50, up 25%, and for the full year, it reached $1.75, up 17% [3][12] - Gross margins remained strong at approximately 77% for the year and 75% for Q4 [3][11] Business Line Data and Key Metrics Changes - MRI-compatible infusion pump systems contributed $9.1 million in Q4, up 20% year-over-year, while patient vital signs monitoring systems contributed $7.1 million, up 7.5% [10] - Disposable revenue grew 18% to $4.3 million, reflecting increased utilization of devices [10][11] Market Data and Key Metrics Changes - Domestic sales accounted for 81% of total revenue in Q4 and 84% for the full year, indicating strong U.S. performance [11] - There are approximately 6,400 5+-year-old 3860/3861 pump channels in the U.S. market that are up for replacement [6] Company Strategy and Development Direction - The company anticipates a significant increase in revenue from the new 3870 MR IV pump, with an expected average selling price increase of 10%-14% [4] - The strategy includes targeting an additional 1,000 replacement sales annually from existing 5+-year-old units, aiming for a $100 million-plus revenue run rate during 2026 [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a $100 million-plus revenue run rate during 2026, driven by the new product launch and existing product sales [7][8] - The company is focused on optimizing the new 3870 pump based on initial user feedback before the broader launch [15][31] Other Important Information - Cash flow from operations was $5.9 million for Q4 and $24.9 million for the full year, with cash and cash equivalents ending at $51.2 million [12] - The company is working on a next-generation MRI monitor expected to launch in 2028 [21] Q&A Session Summary Question: Initial market feedback on the 3870 pump - Management reported very positive feedback from initial users, leading to confidence in scaling the launch [15][16] Question: Gross margin trends - Management expects gross margins to remain stable in the first half of the year, with potential improvement in the second half due to higher volumes and ASP [18][19] Question: R&D efforts post-3870 launch - The R&D team is already working on a next-generation MRI monitor, with plans for a market launch in 2028 [20][21] Question: Strength of disposables and services - Management indicated that disposable revenue growth is expected to align with capital sales, with potential for increased utilization with the new 3870 pump [26][27] Question: Inventory levels and backlog for the 3860 - Management is closely monitoring inventory levels to ensure fulfillment of backlog while transitioning to the 3870 [28][29] Question: Regulatory updates for the 3870 in Europe and Japan - Management confirmed that CE mark approval is expected by the end of 2026, with Japan clearance anticipated by summer 2027 [32]

Q3 Fiscal 2026 Financial Results February 5, 2026 Management Presenters Scott Barbour President and Chief Executive Officer Scott Cottrill Executive Vice President, Chief Financial Officer Craig Taylor Forward Looking Statements Certain statements in this press release may be deemed to be forward -looking statements. These statements are not historical fac ts but rather are based on the Company's current expectations, estimates and projections regarding the Company's business, operations and other factors r ...

Financial Data and Key Metrics Changes - The meeting discussed the election of directors, advisory vote on executive compensation, and the ratification of Ernst & Young as the independent registered public accounting firm for the fiscal year ending August 31, 2026 [2][9] - The advisory vote on executive compensation was approved by no less than 98% of the shares present and voting [11] - The ratification of Ernst & Young was approved by no less than 99% of the shares present and voting [11] Business Line Data and Key Metrics Changes - No specific data on business line performance was provided during the meeting [2][4] Market Data and Key Metrics Changes - No specific market data or metrics were discussed during the meeting [2][4] Company Strategy and Development Direction - The company is focused on maintaining strong governance through the election of directors and ensuring transparency in executive compensation [2][9] - The selection of Ernst & Young as the independent auditor indicates a commitment to high standards of financial reporting and compliance [11] Management Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting [2][4] Other Important Information - The meeting was held virtually, allowing shareholders to participate via a web portal and phone [2] - A quorum was confirmed with at least 95% of shares present, allowing the meeting to proceed [6][7] Q&A Session Summary Question: Are there any questions from shareholders? - No questions were submitted through the portal during the meeting [13][14]

Financial Data and Key Metrics Changes - Operating earnings per share for 2025 reached a record $2.16, reflecting strong performance compared to 2024 [9] - Customer deposits increased by $449 million, with a 25% year-over-year growth in consumer demand deposit account openings [10] - Net interest margin improved by 9 basis points to 3.51%, ending the fourth quarter at 3.59% despite Fed rate cuts [18] - Operating return on assets increased by 17 basis points to 1.28% [17] - Tangible book value per share grew by 15% [19] Business Line Data and Key Metrics Changes - Non-interest income, excluding certain gains and losses, rose to $277 million, up almost 7% year-over-year [13] - Commercial fees increased by 8%, driven by a 17% growth in cash management revenue [14] - Wealth assets under management surpassed $17 billion, with a 17% increase in referrals from financial centers [15] Market Data and Key Metrics Changes - The loan-to-deposit ratio remained stable at 91% [29] - Total deposits grew by $257 million, or 3.9%, with balanced growth across categories [27] - Municipal deposits decreased by $254 million, while other wholesale funding declined by $29 million [28] Company Strategy and Development Direction - The company aims to create long-term value by growing the business and delivering effectively for customers [9] - The acquisition of Blue Foundry Bancorp is expected to strengthen the company's footprint and community banking model [21] - The company plans to return to historical loan growth rates in the mid-single-digit range in 2026 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit loan growth in 2026, citing the moderation of previous headwinds [46] - The company is optimistic about opportunities in 2026, focusing on continued strength and growth [22] - Credit metrics improved, with non-performing assets declining to 0.58% of total assets [37] Other Important Information - Operating expenses grew by 1.9% in 2025, but would have decreased by 2.7% when normalizing for prior year expenses [17] - The company repurchased $59 million of common stock and increased its dividend [19] - The effective tax rate is projected to be between 18.5% and 19.5% for 2026 [40] Q&A Session Summary Question: Loan growth guidance for 2026 - Management indicated that headwinds from strategic actions in 2025 will moderate, allowing for a return to mid-single-digit growth [46] Question: Pay downs assumptions - Management expects normal portfolio pay downs and prepayments to remain consistent year-over-year [50] Question: Loss provision guidance - The allowance for credit losses is expected to drift lower in a stable credit environment, with charge-offs remaining flat [52] Question: Loan mix changes with new hires - Management aims for diversified growth across all loan segments, with opportunities in CRE, C&I, and business banking [60] Question: Deposit growth and composition - Management noted strong momentum in consumer and small business deposits, with a focus on low-cost operating deposits [71] Question: Commercial interest rate swap income - Swap income is expected to correlate with originations, which have shown growth in the fourth quarter [78] Question: Other fee income expectations - Other fee income is expected to normalize around $2.5 million, influenced by quarterly volatility [79]

PresentationI'd now like to turn the call over to Steven Gitlin, Vice President of Investor Relations. You may begin.Thank you for standing by, and welcome to the Karman Space & Defense Expands into High-Priority Maritime Defense Market with Agreement to Acquire Seemann Composites and Materials Sciences Conference Call. [Operator Instructions]Steven GitlinVice President of Investor Relations Good afternoon, and welcome to Karman's investor conference call to discuss our acquisition of Seemann Composites and ...

Article contentIn certain cases, forward-looking statements can be identified by the use of words such as “anticipates”, “approximately”, “believes”, “budget”, “estimates”, expects”, “forecasts”, “guidance”, intends”, “plans”, “scheduled”, “target”, or variations of such words and phrases, or statements that certain actions, events or results “be achieved”, “could”, “may”, “might”, “occur”, “should”, “will be taken” or “would” or the negative of these terms or comparable terminology. In this document certai ...